- Report
- October 2021
- 111 Pages
North America, Europe, ... North America, Europe, Latin America
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 146 Pages
Global
From €3367EUR$3,528USD£2,821GBP
€3961EUR$4,150USD£3,318GBP
- Report
- December 2023
- 150 Pages
Global
From €3818EUR$4,000USD£3,199GBP
- Report
- May 2023
- 526 Pages
Global
From €3985EUR$4,175USD£3,338GBP
- Report
- July 2024
- 94 Pages
Global
From €3500EUR$3,929USD£3,035GBP
From €2675EUR$3,003USD£2,320GBP
- Book
- December 2022
- 656 Pages
- Book
- June 2021
- 592 Pages
- Book
- October 2019
North America
- Book
- March 2019
North America

The Tropical Disease market is a subset of the Pharmaceuticals industry that focuses on the development of treatments for diseases that are endemic to tropical and subtropical regions. These diseases are caused by a variety of pathogens, including viruses, bacteria, fungi, and parasites. The market is driven by the need to address the high burden of disease in these regions, as well as the potential for new treatments to be developed for diseases that are not yet treatable.
The Tropical Disease market is highly competitive, with a number of large pharmaceutical companies and smaller biotechnology firms vying for market share. Companies in the market include GlaxoSmithKline, Merck, Novartis, Sanofi, Pfizer, Johnson & Johnson, and Bristol-Myers Squibb. Additionally, there are a number of smaller biotechnology companies that are focused on developing treatments for tropical diseases, such as Gilead Sciences, Inovio Pharmaceuticals, and Moderna Therapeutics. Show Less Read more